The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Schizophrenia

@article{Osser2013ThePA,
  title={The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Schizophrenia},
  author={David N. Osser and Mohsen Jalali Roudsari and Theo C. Manschreck},
  journal={Harvard Review of Psychiatry},
  year={2013},
  volume={21},
  pages={18–40}
}
This article is an update of the algorithm for schizophrenia from the Psychopharmacology Algorithm Project at the Harvard South Shore Program. A literature review was conducted focusing on new data since the last published version (1999–2001). The first-line treatment recommendation for new-onset schizophrenia is with amisulpride, aripiprazole, risperidone, or ziprasidone for four to six weeks. In some settings the trial could be shorter, considering that evidence of clear improvement with… 
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression.
TLDR
This algorithm for unipolar nonpsychotic depression for inpatients with severe melancholic depression and acute safety concerns suggests electroconvulsive therapy (or ketamine if ECT refused or ineffective) may be the first-line treatment.
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Generalized Anxiety Disorder.
TLDR
This revision of the GAD algorithm responds to issues raised by new treatments under development (such as pregabalin) and organizes the evidence systematically for practical clinical application.
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Acute Mania
TLDR
This new algorithm for the pharmacotherapy of acute mania was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program and presupposes that clinicians have made an accurate diagnosis, decided how to manage contributing medical causes, discontinued antidepressants, and considered the patient’s childbearing potential.
The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression -
TLDR
This heuristic further refines the previous PAPHSS analysis of the available evidence for pharmacological treatment of psychotic depression, and suggests monotherapy with a TCA may be more effective than an SNRI or SSRI.
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
TLDR
The role of oral olanzapine is revisited in the management of patients with schizophrenia, including those with recently diagnosed schizophrenia, those with an established schizophrenia diagnosis who experience acute exacerbations, those receiving long-term antipsychotics treatment as a maintenance intervention, and those with suboptimal response to antipsychotic treatment, including treatment resistance.
Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study
TLDR
Second-generation antipsychotic prescribing predominates, but guidelines are often overlooked when choosing olanzapine notwithstanding lower initial dosages, and EIP services should include proactive support for optimising medicines in line with evidence-based guidelines.
A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia
Abstract Clinical guidelines provide evidence-based recommendations to regulate pharmacological treatment of psychotic disorders. However, the quality of evidence, country of origin, and publication
Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
TLDR
Paliperidone palmitate 3-monthly injection appears to be a viable treatment option for patients previously maintained on PP1M, however, to truly establish the place of PP3M in therapy relative to other oral antipsychotics and LAIs, more research is needed.
...
1
2
3
...

References

SHOWING 1-10 OF 242 REFERENCES
The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression.
This updated version of the bipolar depression algorithm of the Psychopharmacology Algorithm Project at the Harvard South Shore Program aims to provide an organized, sequential, and
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Psychotic Depression
TLDR
This new version of the psychotic depression algorithm has been developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program and shows promise in treating inpatients with severe psychotic depression.
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Posttraumatic Stress Disorder
TLDR
It is found that SSRIs and SNRIs are not as effective as previously thought, and that awareness of their long‐term side effects has increased, and new evidence suggests that addressing fragmented sleep and nightmares can improve symptoms.
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting
TLDR
When the first atypical antipsychotic is inadequate, switching to the second is worth trying, although some remain treatment-refractory, as in this open-label study of patients with schizophrenia.
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
TLDR
The Texas Medication Algorithm Project (TMAP) algorithm for schizophrenia was updated and revised to incorporate the following recommendations, meant to provide a framework for clinical decision making, not to replace clinical judgment.
Olanzapine versus haloperidol in the treatment of first episode psychosis
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
TLDR
An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
Ziprasidone versus other atypical antipsychotics for schizophrenia.
TLDR
Ziprasidone was a less acceptable treatment than olanzapine and less efficacious than amisulpride, but not than the other second generation antipsychotic drugs.
Amisulpride versus other atypical antipsychotics for schizophrenia.
TLDR
Amisulpride may be somewhat more effective than ziprasidone, and more tolerable in terms of weight gain and other associated problems than olanzapine and risperidone and other second generation antipsychotic drugs.
...
1
2
3
4
5
...